The Frontier of Penile Implants in Phalloplasty: Is the ZSI 475 FTM what we have been waiting for?

Mirko Preto1 · Gideon Blecher2,3 · Massimiliano Timpano1 · Paolo Gontero1 · Marco Falcone4

Received: 12 July 2020 / Revised: 23 November 2020 / Accepted: 2 December 2020 / Published online: 22 January 2021
© The Author(s) 2021. This article is published with open access

Penile prosthesis (PP) implantation represents the final stage of neo-phallus creation, and is arguably the most exciting step for a transgender patient. It transforms an otherwise aesthetic organ, which may or may not provide voiding capabilities, into a functional sexual organ. This aspect remains an essential component for some trans-males undergoing gender genital affirming surgery (GGAS), defining their masculinity and supporting their quality of life [1, 2].

Whilst there have been advances in phalloplasty techniques, as well as developments in the implant technologies, there unfortunately remains significant complications which must be stomached by both patients and health care providers. If these issues were to be resolved, say by the ideal PP, one would assume that both patients and surgeons would more readily access phalloplasty as part of gender dysphoria management. Unfortunately however, the perfect prosthesis, particularly in phalloplasty, eludes us. Ideally it would be completely inert and remain free from infection. It would also provide perfect rigidity and stability when erect and be easily incorporated into the pelvis. Continuing our dream of a problem free implant, it would remain permanently free from mechanical damage and would never find its way eroding through local tissues. So what is the reality for trans-males undergoing PP implantation in a phalloplasty?

In terms of PP, both malleable and inflatable devices have been implanted. Hydraulic implants are often utilised due to the more natural appearance in the flaccid state, as well as because of the reduced apical pressure on the phallic tissues, thus minimising the risk of distal erosion [3–5]. It is not only erosion that poses a problem: it seems inequitable that cis-males whom require PP, whilst experiencing potential complications, are much less exposed to such problems than trans-gender males. The incidence of post-operative complications are dramatically higher in phalloplasty, compared to a native phallus [6–9].

The main surgical complications remain implant infection, erosion or malposition. Patient reported outcomes (PROs) of interest are varied but many would include sensation, orgasmic function, ability to engage in penetrative intercourse, as well as overall satisfaction, as key measures. Whilst there is extensive literature regarding PP in cis-males, the research documenting outcomes in phalloplasty is much more limited.

Six [3–6, 10–12] major studies (implant n > 40) have been published on this topic, most of them being relatively small volume (implant n < 247, mean patient n = 97), retrospective, with high heterogeneity in terms of implant models, techniques and outcome measures [3–6, 10–12] (Table 1).

Survival rates for PP in phalloplasty have remained significantly lower than in non-phalloplasty cohorts, with 5 year PP survival ranging from 75 to 78% [3, 5]. Infection thus remains a common reason for explant, occurring in about 8.5–17.8% of cases [3–6, 11, 12]. Contemporary comparative infection rates in non-phalloplasty groups, remain much lower and vary from 1.1 to 1.7% [6].

Mechanical failure, cylinder malposition and erosion rates reported in GGAS are unfortunately significantly higher than those reported in genetic males. Mechanical failure develops in 5 to 22% of cases [3–6, 11, 12],
| Author            | Year | Patients (number) | Follow up (months) | Implants (number) | Model of penile implant (number, %) | Overall Revision rate (%) | Infection (%) | Mechanical failure (%) | Dysfunction/ malposition (%) |
|-------------------|------|-------------------|--------------------|-------------------|-------------------------------------|---------------------------|---------------|------------------------|-----------------------------|
| Falcone [3]       | 2016 | 247               | 20                 | 328               | AMS700CX (226, 68.9%) AMS 700 CXM/R (31, 9.4%) Coloplast Titan (58, 17.7%) Ambicor (13, 3.9%) | 8,5                       | 43.3          | 15.4                   | 19.4                         |
| Hoebeke [4]       | 2009 | 129               | 30.2               | 185               | Dynaflex (9, 6.9%) AMS700CX/CXM (50, 38.7%) AMS700CX Inhibizone (17, 13.3%) Ambicor (47, 36.5%) Coloplast Titan (6, 4.6%) | 41.1                      | 11.9          | 22                     | - Erosion 8.1 - Malposition 14.6 TOT 22.7 |
| Van der Sluis [5] | 2019 | 32                | 55                 | 45                | Dynaflex (13, %) Ambicor (3, %) Coloplast Genesis (14, %) AMS Spectra (2, %) | 44                        | 17.8          | 11.1                   | - Erosion 6.7 - Malposition 4.4 TOT 11.1 |
| Neuville [6]      | 2016 | 69                | 48                 | 95                | AMS Ambicor (90, 94.8%) AMS700 CXR/CX/600 (5, 5.2%) | 37.7                      | 9.6           | 10.5                   | - Erosion 4.2 - Malposition 12.6 TOT 16.8 |
| Djordjevic [11]   | 2019 | 129               | 43                 | 61                | Coloplast Genesis 39 AMS 700LGX 22 | 6.6                       | 3.3           | 5.1                    | NA                          |
| Leriche [13]      | 2008 | 38                | 110                | 49                | Ambicor AMS 600 AMS 700S | 37                        | 29            | 29 (infection included) | NA                          |
| Neuville [14]     | 2019 | 20                | 9                  | 21                | ZSI 475 FtM | 18.9                      | 4.7           | 9.5                    | 4.7                         |
| Verla [15]        | 2020 | 46                | 12                 | 46                | ZSI 475 FtM | 20                        | 11            | 4.3                    | - Erosion 2.2 - Malposition 4.3 TOT 6.5 |
malpositioning ranges from 4.4-19.4% [3–6] and erosion occurs in 4.2-8.1% [4–6].

These higher incidences of complications result in more frequent PP revision surgery, which has been described ranging from 37 to 44% (mean follow up 45 months). Only Djordjevic et al. [11] in their series reported a significant lower revision rate, of 6.6% (mean follow up 43 months).

Regarding functional outcomes, data are even more sparse; few studies have analyzed the satisfaction rates and PROs. In the two studies which reported device cycling, all patients were able to cycle the PP [3, 11]. Despite significant complications as described above, overall satisfaction rates reached 88% [3], remarkably comparable to non-phalloplasty males undergoing PP. Phalloplasty patients have been able to engage in penetrative intercourse in 51–77% of cases [3, 12].

**Whilst complications are generally poorer, the operation has its own specific hurdles**

The anatomical lack of corpora cavernosa is one of the major differences when implanting prostheses in transmales. Indeed, the lack of the tunica albuginea, which normally forms a protecting envelope around the cylinders, may affect their durability. Until recently, surgeons had to design their own makeshift solutions to overcome the absence of natural housing for the cylinders.

To avoid erosion, Mukherjee described an incorporated pouch, into which a removable prosthesis can be placed when required [13]. More commonly nowadays, surgeons created a makeshift prosthetic Dacron sock, to anchor the proximal cylinder to the pubic bone. Unfortunately, Dacron may be in part to blame for increasing the risk of infection and PP mechanical failure [3, 4].

Looking back at their clinical experience, most of the reconstructive surgeons complained of the absence of a specifically designed PP for phalloplasty over years [3, 12]. Common thought was that having a specifically designed device for transgender patients with specific materials and technical features could have reduced the incidence of complications.

Only recently in 2016, was a phalloplasty specific implant ZSI-475 FTM (Zephyr Surgical Implants, Geneva, Switzerland) designed to address some of these issues [14]. It is composed by a single inflatable cylinder with the diameter of 21 mm protected by a distal glans-shaped stopper of 25 mm. Moreover, it provides an incorporated anchorage plate, in the proximal part of the cylinder, composed of stainless steel and silicone to be sealed with four non-absorbable stitches to the pubic periosteum. These two features removed the necessity for synthetic socks and caps.

Finally, the pump is testicle-shaped to improve aesthetical appearance of the scrotum (Figs. 1 and 2). It was also hoped to reduce the intraoperative time as well as the risk of infection, mechanical failure and erosion since no foreign materials are in contact with the PP.

The data on the ZSI 475 FTM rests upon our own outcomes as well as two other published papers [14–16]. The first report of the ZSI implant in 2016 (n = 20), reported 80% implant survival at a mean of 9 months. Infection (4.7%), mechanical failure (9.5%) and malposition (4.7%) were causes for explant [14].

A major limitation when evaluating the efficacy of PP implantation in transgender men is the lack of any validated tool to inquire patients’ satisfaction. Indeed, investigators were forced to use non-validated questionnaires to evaluate functional outcomes.

Penetration ability (of those patients who had their implants remaining in situ) ranges from 85 to 93% and compares favourably to other implants in phalloplasty 23–77% [3, 11].
Recently, Verla et al. described their initial experience with ZSI 475 FtM PP in 39 trans-men and 7 cis-men after a median follow up of 12 months (SD 8–18) [15]. Infection (11%), mechanical failure (4.3%) and malposition (4.3%) and distal cylinder protrusion (2.2%) were causes for revisional surgery with explant in 20% of cases. The reported explant free implant survival rate was 83% at 6, 12 and 18 months respectively.

That said, there is very limited data available and factors such as personal/relationship situation, psychological factors and phalloplasty dimensions may play a role.

In order to active the ZSI 475 FtM PP, ~60% of patients were fully satisfied with the pump function [14] in one study whilst 100% of patients in our small series felt that the device was easy to cycle.

Orgasm (ZSI PP) has been achieved in 60% of patients [14], this value may appear low compared to general PP implanted series but it is our opinion however, that other factors are involved here rather than the PP itself in transgender patients.

Overall satisfaction rates have been reported with 93% of patients either satisfied/very satisfied with the ZSI device [14], comparable to 88% reporting full satisfaction for a mixed cohort of AMS and Coloplast implants [3].

Our own experience, between April 2019 and January 2020, of five patients, with median follow up of 12 months [IQR 8–17], demonstrates that all patients still had their original prosthesis in place. Median age at implantation was 32 [IQR 19–48] years and median time elapsed between phalloplasty and PP implantation was 12 months [IQR 8–20]. Median operative time was 95 min [80–120] and the distal silicon stopper needed to be modified in a single case to ensure an appropriate fit. No device infection occurred in our series and none required revision surgery. In one case, malposition led to a minor dorsal phallus curvature (<30°), which was managed conservatively; the patient was able to engage in penetrative sexual activity. PRO’s were evaluated through a non-validated satisfaction questionnaire (Table 2). Overall, all patients were able to cycle the device, 4/5 (80%) patients had engaged in penetrative sexual intercourse, all of whom had no pain during intercourse. 3/5 (60%) had achieved orgasm and 4/5 (80%) were fully satisfied with cosmetic and functional outcome of the total phallic reconstruction. Although these numbers and the duration of follow up limited, it compares with other published data.

Thus whilst the phalloplasty surgical community has long awaited dedicated technologies and implants, the ZSI-475 FtM appears to claim some benefits. However, little can be solidly concluded at this early stage as we eagerly await further objective, well planned trials to assess both surgical complications, implant survival, and patient reported outcomes. May this be the first of a series, of exciting new developments for trans phalloplasty prosthetics, brought to fruition together with well documented clinical and subjective outcome reporting.

### Compliance with ethical standards

**Conflict of interest** GB is an Advisory Board member for Coloplast. The remaining authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

### References

1. Pigot GLS, Sigurjónsson H, Ronkes B, Al-Tamimi M, van del Sluis WB. Surgical experience and outcomes of implantation of the ZSI 100 Fm malleable penile implant in transgender men after phalloplasty. J Sex Med. 2020;17:152–8.
2. van de Grift TC, Pigot GLS, Kreukels BPC, Bouman MB, Mul-lender MG. Transmen’s experienced sexuality and genital gender-affirming surgery: Findings from a clinical follow-up study. J Sex Marital Ther. 2019;45:201–5.
3. Falcone M, Garaffa G, Gillo A, Dente D, Christopher AN, Ralph DJ. Outcomes of inflatable penile prosthesis insertion in 247 patients completing female to male gender reassignment surgery. BJU Int. 2018;121:139–44.
4. Hoebeke PB, Decaestecker K, Beysens M, Opdenakker Y, Lumen N, Monstrey SM. Erectile implants in female-to-male transsexuals: Our experience in 129 patients. Eur Urol. 2010;57:334–40.
5. van der Sluis WB, Pigot GLS, Al-Tamimi M, Ronkes BL, de Haseth KB, Özer M, et al. A retrospective cohort study on surgical outcomes of penile prosthesis implantation surgery in transgender men after phalloplasty. Urology. 2019;132:195–201.
6. Neuville P, Morel-Journel N, Maucourt-Boulch D, Ruffion A, Paparel P, Terrier JE. Surgical outcomes of erectile implants after phalloplasty: Retrospective analysis of 95 procedures. J Sex Med. 2016;13:1758–64.
7. Puckett CL, Montie JE. Construction of male genitalia in the transsexual, using a tubed groin flap for the penis and a hydraulic inflation device. Plast Reconstr Surg. 1978;61:523–30.
8. Levine LA, Zachary LS, Gottlieb LJ. Prosthesis placement after total phallic reconstruction. J Urol. 1993;149:593–8.
9. Carson CC III, Mulcahy JJ, Harsch MR. Long-term infection outcomes after original antibiotic impregnated inflatable penile prosthesis implants: Up to 7.7 years of follow-up. J Urol. 2011;185:614–8.
10. Zielinski T. Phalloplasty using a lateral groin flap in female-to-male transsexuals. Acta Chir Plast. 1999;41:15–19.
11. Djordjevic ML, Bencic M, Kojovic V, Stojanovic B, Bizic M, Kojic S, et al. Musculocutaneous latissimus dorsi flap for phalloplasty in female to male gender affirmation surgery. World J Urol. 2019;37:631–7.
12. Leriche A, Timsit MO, Morel-Journel N, Bouillot A, Dembele D, Ruffion A. Long-term outcome of forearm free flap phalloplasty in the treatment of transsexualism. BJU Int. 2008;101:1297–1300.
13. Mukherjee GD. Use of groin and mid-thigh flap in reconstruction of penis with penile and perineal urethra and a dorsal skin-lined socket for a removable prosthesis. Ann Plast Surg. 1986;16:235–41.
14. Neuville P, Morel-Journel N, Cabelguenne D, Ruffion A, Paparel P, Terrier JE. First outcomes of the ZSI 475 FTM, a specific prosthesis designed for phalloplasty. J Sex Med. 2019;16:316–22.
15. Verla W, Goedertier W, Lumen N, Spinoit AF, Waterloos M, Waterschoot M, et al. Implantation of the zephyr zsi 475 ftm erectile device in cis- and transmen after phalloplasty; initial experience and prospective analysis of surgical outcome. J Urol. 2020;203:4S.
16. Terrier JÉ, Courtois F, Ruffion A, Morel, Journel N. Surgical outcomes and patients satisfaction with suprapubic phalloplasty. J Sex Med. 2014;11:288–98.